Clinical trials: Single Coronary Vessel Disease
Healthy Volunteers
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
- Trial name
- NCT03001297
- Testing
- MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Heart Diseases, Hypertension
Effectiveness of Valsartan Alone vs Combination Therapy in Hypertensive Heart Disease
Hypertension is a major global health problem, affecting about 30% of people and up to two-thirds of those over 60 years. Its prevalence has increased significantly, with over one billion adults affected worldwide and expected to…
- Trial name
- VALHCT-HHD (NCT07544888)
- Testing
- Valsartan + Hydrochlorothiazide
- Where
- Pakistan
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Shaikh Zayed Hospital, Lahore
Healthy
Japan Central Aortic Pressure Prospective Study
Purpose of the study 1. The predictive value of central aortic pressure and aortic pulse wave velocity (PWV) in a Japanese population is not known.
- Trial name
- J-CARP (NCT01243840)
- Where
- Japan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Yoshio Matsui
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01496261
- Testing
- Clopidogrel and Aspirin, Fixed dose combination of clopidogrel/aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Ischemic Heart Disease
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
- Trial name
- NCT01847391
- Testing
- GS-6615
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Myocardial Infarct
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
- Trial name
- NCT01264783
- Testing
- RNS60
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Revalesio Corporation
Atherosclerosis
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days.
- Trial name
- NCT00411073
- Testing
- Darapladib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, Risk Factor
Asan Medical Center CCTA Registry
A total of 9269 adults who received CCTA scans for coronary disease evaluation during a general medical checkup at the Health Screening and Promotion Center in Asan Medical Center, Seoul, Korea between January 2007 and December…
- Conditions
- Coronary Artery Disease, Risk Factor, Computed Tomography
- Trial name
- NCT06036901
- Testing
- Coronary CT
- Volunteers
- 6,343 people, healthy volunteers welcome
- Sponsor
- CardioVascular Research Foundation, Korea
Pulmonary Hypertension, Heart Failure
Frailty in Children With Cardiac Disease
Frailty is a complex biologic syndrome of diminished physiologic reserve that leads to decreased resistance to stressors and is associated with adverse health outcomes.
- Conditions
- Pulmonary Hypertension, Heart Failure, Single Ventricle
- Trial name
- NCT02999438
- Testing
- Actigraph to check activity levels at home
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Coronary Artery Disease, Ischemic Heart Disease
Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models
This is a prospective, case-control, single-center, observational, non-randomized study. It is designed to evaluate the diagnostic accuracy of functional tests involving physical exertion monitored via a 12-lead ECG, combined…
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Chronic Coronary Disease, Angina Pectoris
- Trial name
- NCT06181799
- Testing
- Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).
- Where
- Russia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C.
- Conditions
- Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
- Trial name
- NCT03888716
- Testing
- KL1333
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Abliva AB
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453
The purpose of this study is to assess the safety and tolerability of BIA 5-453 after single oral doses
- Trial name
- NCT02845037
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Acute Coronary Syndrome
Phase I Study of GW856553 (Losmapimod)
This study is the first study of losmapimod in Japanese subjects. This study will be a single-center, single blind, phase I and two part study to characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profiles…
- Trial name
- NCT01648192
- Testing
- Losmapimod for single dose, Losmapimod for repeat dose
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Myocardial Infarction
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction
The aim of this study is to determine the immuno-modulatory mechanistic effects of colchicine in patients with myocardial infarction (MI).
- Trial name
- NCT02995512
- Testing
- Colchicine 0.6 mg tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hypertension, Chronic Stable Angina
Bioequivalency Study of Amlodipine Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fed conditions using a single-dose, randomized, 2-treatment, 2-period…
- Conditions
- Hypertension, Chronic Stable Angina, Vasospastic Angina
- Trial name
- NCT00601302
- Testing
- Amlodipine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Hypertension, Heart Failure
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc.
- Trial name
- NCT04967443
- Testing
- Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
COPD, Hypertension
Sleepiz One+ Versus Capnography and Electrocardiography
EtCO2, or exhaled carbon dioxide, is a non-invasive and commonly used measure for respiratory rate and function. It can be easily monitored using a device called a capnograph, which consists of a sensor that is placed near the…
- Conditions
- COPD, Hypertension, Sleep Apnea, Asthma
- Trial name
- SPZCAP (NCT05712226)
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Coronary Artery Disease
A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers
The need exists for alternatives to 99mTc based perfusion radiotracers for cardiac patient management. An alternative radiotracer, I123-CMICE-013, has been developed at the Canadian Molecular Imaging Center of Excellence (C-MICE)…
- Trial name
- CMICE (NCT01558362)
- Testing
- 123I-CMICE-013
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Blood Pressure
Performance of the Aktiia Optical Blood Pressure Monitoring Device Against Double Auscultation
This study with N = 225 participants (1 cohort of a minimum of 85 and maximum of 140 participants, and an additional cohort with 85 participants) over 9 visits has been designed to assess the accuracy of Aktiia.product-us…
- Conditions
- Hypertension, Blood Pressure, Heart Rate
- Trial name
- NCT05236348
- Testing
- Aktiia.product-us
- Where
- Switzerland
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Aktiia SA